Cadrenal Therapeutics Receivables

The latest receivables for CVKD is $5.5K as of March 2026. That compares with $25K in the prior-year period — down 77.8% year over year. Investors often review this figure alongside Cadrenal Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, CVKD's receivables moved from $25K to $5.5K — a 77.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Cadrenal Therapeutics's operating scale or balance-sheet position.

A receivables figure of $5.5K for CVKD is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting CVKD's receivables ($5.5K), review year-over-year change from $25K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.